1-2 of 2
Julia Wilkerson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor

Arup R. Chakraborty, Robert W. Robey, Victoria L. Luchenko, Zhirong Zhan, Richard L. Piekarz, Jean-Pierre Gillet, Andrew V. Kossenkov, Julia Wilkerson, Louise C. Showe, Michael M. Gottesman, Nathan L. Collie, Susan E. Bates
Journal: Blood
Blood (2013) 121 (20): 4115–4125.
https://doi.org/10.1182/blood-2012-08-449140
Published: 2013
Includes: Supplemental data
Journal Articles

Assessment of Tumor Growth (g) and Regression (d) Rate Constants in Patients with Multiple Myeloma (MM) Shows That the Superiority of Bortezomib with Liposomal Doxorubicin (PLD+B) Over Bortezomib Alone (B) Is a Result of Reduced Growth of Refractory Tumor Cells and Not of Higher Regression Rates, and Provides An Earlier Efficacy Endpoint That Allows for Comparison Across Trials

Elisabet E. Manasanch, MD, Julia Wilkerson, BS, Liang Xiu, Sen Zhuang, MD, PhD, Susan Bates, MD, Wilfred Stein, PhD, Antonio T Fojo, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 5113.
https://doi.org/10.1182/blood.V118.21.5113.5113
Published: 2011